15 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
18 Oct 23
Regulation FD Disclosure
11:31am
the expansion of the T-cell repertoire diversity as well as HSV-1 immune status, correlate with survival suggesting that CAN-3110 can enhance anti-cancer immune … . Accordingly, we observed increased diversity of the T-cell receptor repertoire after a single injection of CAN-3110 in recurrent HGG patients. We have
8-K
EX-99.1
CADL
Candel Therapeutics Inc
6 Dec 22
Regulation FD Disclosure
8:01am
- 0.00095) B= baseline P= progression/off study 66
Combination of CAN-2409 and nivolumab results in expansion of TCR clone density, diversity … and clonality Density Diversity Clonality Suggested Baseline Week 3 Week 5 Week 11 Progression Suggested Baseline Week 3 Week 5 Week 11 Progression Baseline Week
DEF 14A
CADL
Candel Therapeutics Inc
2 Sep 22
Definitive proxy
8:30am
and Procedures for Director Candidates, or the Director Guidelines, provide that the value of diversity should be considered in determining director … , we do not have a formal policy concerning the diversity of the board of directors. Our priority in selection of board members is identification
8-K
EX-99.1
CADL
Candel Therapeutics Inc
18 Nov 22
Other Events
8:30am
in multiple tumor lesions following a single injection of CAN-3110. Diversity of the T cell receptor repertoire after CAN-3110 administration
8-K
EX-99.1
44v9qi gt7vlc
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
k45q6c8nep1xr6q2hyf2
9 Nov 23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
8:16am
S-1/A
7abx22i6 b2
16 Jul 21
IPO registration (amended)
6:07am
S-1
knw0evup
25 Jun 21
IPO registration
5:28pm
DRS/A
jyhy9 k415v9ak
31 Mar 21
Draft registration statement (amended)
12:00am
424B4
4nq78mg 09cltj
28 Jul 21
Prospectus supplement with pricing info
4:02pm
- Prev
- 1
- Next